Caris Life Sciences,�Inc. (CAI) vs Kymera Therapeutics, Inc. (KYMR)
- Caris Life Sciences,�Inc. CAI 30.56 −3.78%
- Kymera Therapeutics, Inc. KYMR 104.78 −3.11%
Caris Life Sciences,�Inc. and Kymera Therapeutics, Inc. are both Biotechnology companies. Caris Life Sciences,�Inc. and Kymera Therapeutics, Inc. are of similar size ($9.0B and $9.0B). Kymera Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Caris Life Sciences,�Inc. trades at 81.3×. Kymera Therapeutics, Inc. grew revenue faster over the last twelve months: 134.8% against 96.4%. Caris Life Sciences,�Inc. has the higher net margin (8.15% vs −285.3%) and the higher return on invested capital (50.0% vs −26.7%). Across the 17 metrics below, Caris Life Sciences,�Inc. leads on 12 and Kymera Therapeutics, Inc. on 5.
Valuation
Profitability
| Metric | CAI | KYMR | Biotechnology median |
|---|---|---|---|
| Gross margin | 69.66% | 100.00% | 65.16% |
| Operating margin | 15.49% | (333.50%) | 0.00% |
| Net margin | 8.15% | (285.33%) | 0.00% |
| Free cash flow margin | 12.53% | (226.62%) | 0.00% |
| Return on equity | 15.45% | (24.15%) | (56.36%) |
| Return on assets | 7.39% | (21.58%) | (48.04%) |
| Return on invested capital | 49.95% | (26.72%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack